122 related articles for article (PubMed ID: 23597579)
1. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.
de Weerdt I; Eldering E; van Oers MH; Kater AP
Leuk Res; 2013 Jul; 37(7):838-47. PubMed ID: 23597579
[TBL] [Abstract][Full Text] [Related]
2. Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.
Hutchinson CV; Dyer MJ
Br J Haematol; 2014 Jul; 166(1):12-22. PubMed ID: 24749490
[TBL] [Abstract][Full Text] [Related]
3. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
4. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
5. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Robak P; Robak T
Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
[TBL] [Abstract][Full Text] [Related]
6. Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.
Wickremasinghe RG; Prentice AG; Steele AJ
Br J Haematol; 2011 Jun; 153(5):545-56. PubMed ID: 21501136
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
[TBL] [Abstract][Full Text] [Related]
8. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
9. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.
Maly J; Blachly JS
Curr Hematol Malig Rep; 2016 Feb; 11(1):52-60. PubMed ID: 26893063
[TBL] [Abstract][Full Text] [Related]
10. Towards targeted therapy of chronic lymphocytic leukemia.
Niemann CU; Jones J; Wiestner A
Adv Exp Med Biol; 2013; 792():259-91. PubMed ID: 24014301
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).
Pettijohn EM; Ma S
Curr Hematol Malig Rep; 2017 Feb; 12(1):20-28. PubMed ID: 28155013
[TBL] [Abstract][Full Text] [Related]
12. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.
López-Guerra M; Xargay-Torrent S; Pérez-Galán P; Saborit-Villarroya I; Rosich L; Villamor N; Aymerich M; Roué G; Campo E; Montserrat E; Colomer D
Leukemia; 2012 Jun; 26(6):1429-32. PubMed ID: 22182921
[No Abstract] [Full Text] [Related]
14. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
Mato A; Jauhari S; Schuster SJ
Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia.
Michie AM; Nakagawa R
Hematol Oncol; 2006 Sep; 24(3):134-8. PubMed ID: 16841369
[TBL] [Abstract][Full Text] [Related]
16. Companies in rapid pursuit of Btk immunokinase.
Sheridan C
Nat Biotechnol; 2012 Mar; 30(3):199-200. PubMed ID: 22398595
[No Abstract] [Full Text] [Related]
17. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.
Burger JA
Hematology Am Soc Hematol Educ Program; 2011; 2011():96-103. PubMed ID: 22160019
[TBL] [Abstract][Full Text] [Related]
18. Critical molecular pathways in CLL therapy.
Ferrer G; Montserrat E
Mol Med; 2018 Mar; 24(1):9. PubMed ID: 30134797
[TBL] [Abstract][Full Text] [Related]
19. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells.
Kruse U; Pallasch CP; Bantscheff M; Eberhard D; Frenzel L; Ghidelli S; Maier SK; Werner T; Wendtner CM; Drewes G
Leukemia; 2011 Jan; 25(1):89-100. PubMed ID: 20944678
[TBL] [Abstract][Full Text] [Related]
20. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
